Falana Kimberly, Knight Rob, Martin Camilia R, Goldszmid Romina, Greathouse K Leigh, Gere Joanne, Young Howard, Kuo Winston Patrick
BioPharma Research Council, Tinton Falls, NJ, USA.
Department of Pediatrics, Computer Science and Engineering, University of California San Diego, San Diego, CA, USA.
J Circ Biomark. 2015 Jul 27;4:8. doi: 10.5772/61257. eCollection 2015 Jan-Dec.
Over the past decade, it has become evident that the microbiome is an important environmental factor that affects many physiological processes, such as cell proliferation and differentiation, behaviour, immune function and metabolism. More importantly, it may contribute to a wide variety of diseases, including cancer, inflammatory diseases, metabolic diseases and responses to pathogens. We expect that international, integrative and interdisciplinary translational research teams, along with the emergence of FDA-approved platforms, will set the framework for microbiome-based therapeutics and diagnostics. We recognize that the microbiome ecosystem offers new promise for personalized/precision medicine and targeted treatment for a variety of diseases. The short course was held as a four-session webinar series in April 2015, taught by pioneers and experts in the microbiome ecosystem, covering a broad range of topics from the healthy microbiome to the effects of an altered microbiome from neonates to adults and the long term effects as it is related to disease, from asthma to cancer. We have learned to appreciate how beneficial our microbes are in breaking down our food, fighting off infections and nurturing our immune system, and this information provides us with ideas as to how we can manipulate our microbiome to prevent certain diseases. However, given the variety of applications, there are scientific challenges, though there are very promising areas in reference to the clinical benefits of understanding more about our microbiome, whether in our gut or on our skin: the outlook is bright. A summary of the short course is presented as a meeting dispatch.
在过去十年中，微生物组已成为一个重要的环境因素，影响着许多生理过程，如细胞增殖与分化、行为、免疫功能和新陈代谢。更重要的是，它可能导致多种疾病，包括癌症、炎症性疾病、代谢性疾病以及对病原体的反应。我们预计，随着美国食品药品监督管理局（FDA）批准的平台的出现，国际、综合和跨学科的转化研究团队将为基于微生物组的治疗和诊断奠定框架。我们认识到，微生物组生态系统为个性化/精准医学和针对多种疾病的靶向治疗带来了新的希望。该短期课程于2015年4月作为一个四场网络研讨会系列举行，由微生物组生态系统的先驱和专家授课，涵盖了广泛的主题，从健康的微生物组到微生物组改变对从新生儿到成年人的影响以及与疾病（从哮喘到癌症）相关的长期影响。我们已经了解到我们的微生物在分解食物、抵御感染和滋养免疫系统方面是多么有益，这些信息为我们提供了如何操纵微生物组以预防某些疾病的思路。然而，鉴于应用的多样性，存在科学挑战，尽管在了解更多关于我们的微生物组（无论是在肠道还是在皮肤上）的临床益处方面有非常有前景的领域：前景是光明的。作为会议快报，本文呈现了该短期课程的总结。
